A study found that a diabetes treatment DPP-4 inhibitor prevents Parkinson's disease from progressing.A research team led by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Fecal dipeptidyl peptidase-4 may be used ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors ...

GLP-1RA use was associated with a lower incidence of rheumatic diseases such as rheumatoid arthritis, gout, and ...

DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual ...